Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Voyager Therapeutics Inc (Voyager) is a gene therapy company that discovers, develops and commercializes therapies to treat severe neurological diseases. It is evaluating VY-AADC program for the treatment of advanced Parkinson’s disease; VY-HTT01 to treat Huntington’s disease and VY-FXN01 program targeting Friedreich's ataxia. The company is also investigating therapies against tauopathies including Alzheimer’s disease (AD), frontotemporal lobar degeneration (FTD), progressive supranuclear palsy (PSP) and neurodegeneration. It works in collaboration with Genzyme Corp, Neurocrine Biosciences Inc and AbbVie Biotechnology Ltd to develop its programs. Voyager is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
75 Hayden Avenue, Lexington, Massachusetts, 02421
Website
www.voyagertherapeutics.com
Telephone
1 857 2595340
No of Employees
162
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VYGR (NASD)
Revenue (2022)
$250.0M
511.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
385.1%
(2022 vs 2021)
Market Cap*
$454.7M
Net Profit Margin (2022)
XYZ
146.7%
(2022 vs 2021)
* As of and is in US$
Products and Services
| Products |
|---|
| VY-AADC: Advancing Parkinson's Disease |
| VY-HTT01: Huntington's Disease |
| VY-FXN01: Friedreich's Ataxia |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Contracts/Agreements | In March, the company entered into an agreement with Novartis to develop gene therapies for the treatment of neurological diseases. |
| 2019 | Contracts/Agreements | In February, Voyager Therapeutics and AbbVie partnered to develop and commercialize vectorized antibodies which treat Parkinson's disease and other synucleinopathies. |
| 2019 | Contracts/Agreements | In January, Voyager signed a strategic agreement, worth US$1.8 billion, with Neurocrine Biosciences to develop and commercialize the gene therapy candidates for severe neurological conditions. |
Competitor Comparison
| Key Parameters | Voyager Therapeutics Inc | Intra-Cellular Therapies Inc | Amylyx Pharmaceuticals Inc | Taysha Gene Therapies Inc | Adverum Biotechnologies Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Lexington | New York | Cambridge | Dallas | Redwood City |
| State/Province | Massachusetts | New York | Massachusetts | Texas | California |
| No. of Employees | 162 | 610 | 384 | 52 | 121 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Higgins | Chairman; Director | Executive Board | 2019 | 60 |
| Alfred Sandrock, M.D., Ph.D | President; Director; Chief Executive Officer | Executive Board | 2022 | 65 |
| Peter P. Pfreundschuh | Chief Financial Officer | Senior Management | 2022 | 54 |
| Robin Swartz | Chief Operating Officer | Senior Management | 2022 | 52 |
| Jacquelyn Fahey Sandell | Chief Legal Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer